Tower Research Capital (TRC)’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-8,703
Closed -$130K 6794
2022
Q4
$130K Buy
8,703
+5,964
+218% +$82.6K 0.01% 1625
2022
Q3
$23K Buy
2,739
+2,106
+333% +$16.2K ﹤0.01% 3843
2022
Q2
$4K Sell
633
-813
-56% -$3.94K ﹤0.01% 5337
2022
Q1
$8K Sell
1,446
-12,049
-89% -$49.6K ﹤0.01% 4668
2021
Q4
$63K Buy
13,495
+10,360
+330% +$64.3K ﹤0.01% 2591
2021
Q3
$20K Sell
3,135
-25,629
-89% -$153K ﹤0.01% 3742
2021
Q2
$190K Buy
28,764
+22,649
+370% +$156K ﹤0.01% 1970
2021
Q1
$45K Buy
6,115
+1,502
+33% +$13K ﹤0.01% 3230
2020
Q4
$27K Sell
4,613
-10,181
-69% -$58.3K ﹤0.01% 3677
2020
Q3
$88K Buy
14,794
+12,417
+522% +$61.4K ﹤0.01% 3245
2020
Q2
$12K Buy
2,377
+2,375
+118,750% +$15K ﹤0.01% 3954
2020
Q1
$0 Buy
+2
New +$10 ﹤0.01% 4436
2019
Q4
Sell
-1,471
Closed -$12K 4826
2019
Q3
$12K Sell
1,471
-1,042
-41% -$7.75K ﹤0.01% 2850
2019
Q2
$17K Buy
2,513
+1,863
+287% +$16K ﹤0.01% 2289
2019
Q1
$5K Sell
650
-438
-40% -$4.52K ﹤0.01% 3127
2018
Q4
$17K Sell
1,088
-515
-32% -$11.3K ﹤0.01% 2084
2018
Q3
$53K Buy
1,603
+403
+34% +$10.4K ﹤0.01% 1725
2018
Q2
$27K Buy
1,200
+1,179
+5,614% +$28K ﹤0.01% 2255
2018
Q1
$1K Sell
21
-3,417
-99% -$100K ﹤0.01% 3142
2017
Q4
$96K Buy
+3,438
New +$107K 0.01% 895
2017
Q1
Sell
-108
Closed -$1K 4309
2016
Q4
$1K Sell
108
-4,426
-98% -$29.5K ﹤0.01% 3712
2016
Q3
$40K Buy
4,534
+1,150
+34% +$10.8K ﹤0.01% 1262
2016
Q2
$33K Buy
3,384
+3,220
+1,963% +$31K ﹤0.01% 1872
2016
Q1
$1K Sell
164
-99
-38% -$980 ﹤0.01% 3895
2015
Q4
$3K Sell
263
-556
-68% -$6.61K ﹤0.01% 3577
2015
Q3
$10K Buy
819
+677
+477% +$9.78K ﹤0.01% 2338
2015
Q2
$2K Buy
+142
New +$2.56K ﹤0.01% 3844
2014
Q4
Sell
-10
Closed 5007
2014
Q3
$0 Buy
+10
New +$127 ﹤0.01% 5104
2014
Q2
Sell
-1,950
Closed -$29K 4890
2014
Q1
$29K Buy
+1,950
New +$35K ﹤0.01% 1547
2013
Q3
Sell
-400
Closed -$10K 4983
2013
Q2
$10K Buy
+400
New +$17.1K ﹤0.01% 2395

Tower Research Capital (TRC)'s AVEO Position: Q1 2023 in Review

Tower Research Capital (TRC) sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 8,703 shares — an estimated $130K sold.

Tower Research Capital (TRC) first reported a position in AVEO in Q2 2013 and held it in 30 quarters. The position peaked at $190K in Q2 2021. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

  • Tower Research Capital (TRC) reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 8,703 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $130K.
  • Tower Research Capital (TRC) first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 30 quarters.
  • Tower Research Capital (TRC)'s AVEO Pharmaceuticals, Inc. position peaked at $190K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2023, filed 9 May 2023.